Stargardt Disease (STGD1) research hub

An Open-label, Multicenter, Two Part, Ascending Dose Followed by a Controlled Trial to Assess the Safety and Efficacy of a Subretinal Administration of AAVB-039 in Participants with Stargardt Disease (STGD1) (CELESTE)

This study is testing a new treatment, AAVB-039, for Stargardt disease. It's the first time this treatment is being given to people. Researchers want to see if it's safe and if it helps improve vision or slow down the disease.